Shares of Equillium, Inc. (NASDAQ:EQ – Get Rating) traded up 1% during trading on Tuesday . The company traded as high as $1.05 and last traded at $1.02. 42,255 shares were traded during trading, a decline of 49% from the average session volume of 82,164 shares. The stock had previously closed at $1.01.
Analyst Ratings Changes
Separately, HC Wainwright lifted their price target on Equillium from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, September 27th.
Equillium Stock Performance
The stock has a market cap of $35.10 million, a P/E ratio of -0.44 and a beta of 1.23. The company has a fifty day moving average price of $1.30 and a 200 day moving average price of $1.89. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.13 and a quick ratio of 3.13.
Institutional Investors Weigh In On Equillium
Institutional investors have recently bought and sold shares of the stock. State Street Corp increased its position in shares of Equillium by 13.2% during the 1st quarter. State Street Corp now owns 56,220 shares of the company’s stock valued at $177,000 after purchasing an additional 6,564 shares during the last quarter. Jane Street Group LLC bought a new position in Equillium during the 1st quarter worth approximately $47,000. Dimensional Fund Advisors LP bought a new position in Equillium during the 3rd quarter worth approximately $43,000. Renaissance Technologies LLC bought a new position in Equillium during the 2nd quarter worth approximately $34,000. Finally, Capital CS Group LLC bought a new position in Equillium during the 4th quarter worth approximately $25,000. Institutional investors own 37.64% of the company’s stock.
Equillium Company Profile
Equillium, Inc engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D.
- Get a free copy of the StockNews.com research report on Equillium (EQ)
- High-Yield, Deep-Value Verizon Puts In A Bottom
- Should You Bet Against The Nasdaq 100 With This Inverse ETF?
- Can Coty Stock Emerge in 2023 With Upside
- Insiders Buy Archer Aviation, Is This Stock About To Take Off?
- Intuit Is About To Make a Move, But Which Way?
Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.